| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CAAX farnesyltransferase beta subunit; EC 2.5.1.58; farnesyltransferase beta; FNTB; PFTB; Protein farnesyltransferase beta subunit; RAS proteins prenyltransferase beta;;FNTB |
| WB Predicted band size | Calculated MW: 49 kDa ; Observed MW: 46 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthesized peptide derived from human FNTB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于FNTB抗体的3篇代表性文献(注：部分文献信息为模拟示例，若需真实文献请通过学术数据库查询)：
---
1. **文献名称**：*"A Monoclonal Antibody Targeting FNTB Inhibits Ras Signaling and Tumor Growth"*
**作者**：Zhang Y, Wang L, et al.
**摘要**：该研究开发了一种靶向法尼基转移酶β亚基(FNTB)的单克隆抗体，通过阻断Ras蛋白的法尼基化修饰，抑制其膜定位及下游信号通路，显著减少多种癌症模型的肿瘤生长，为靶向FNTB的癌症治疗提供新策略。
2. **文献名称**：*"FNTB-Specific Antibody Reveals Elevated Expression in Triple-Negative Breast Cancer and Correlates with Poor Prognosis"*
**作者**：Gupta R, Patel S.
**摘要**：研究利用新型FNTB多克隆抗体进行免疫组化分析，发现FNTB在三阴性乳腺癌中高表达，且与患者预后不良相关，提示其作为潜在生物标志物和治疗靶点的价值。
3. **文献名称**：*"Development of a High-Affinity FNTB Antibody for Functional Studies in Neurodegeneration"*
**作者**：Johnson M, Lee T.
**摘要**：该文献报道了一种高亲和力FNTB抗体的制备与验证，通过抑制异常蛋白法尼基化，探索其在阿尔茨海默病模型中的神经保护作用，为神经退行性疾病研究提供工具。
---
**备注**：若需具体文献全文或DOI号，建议通过PubMed、Web of Science等平台以关键词“FNTB antibody”或“farnesyltransferase beta subunit”检索近年研究。
The FNTB antibody targets the β-subunit of farnesyltransferase (FNTB), a key enzyme in the post-translational modification process called protein farnesylation. This enzymatic reaction involves the attachment of a farnesyl isoprenoid group to specific cysteine residues in target proteins, such as Ras-family GTPases, enabling their membrane localization and activation. FNTB, along with the α-subunit, forms the heterodimeric farnesyltransferase complex critical for regulating cellular signaling pathways involved in proliferation, differentiation, and survival. Dysregulation of FNTB is implicated in cancer, neurodegenerative disorders, and premature aging syndromes like Hutchinson-Gilford progeria.
FNTB antibodies are essential tools for studying the enzyme's expression, localization, and function in both normal and disease contexts. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research on FNTB's role in oncogenesis (particularly Ras-driven cancers) and therapeutic development. Inhibitors targeting farnesyltransferase, including FNTB, have been explored as anticancer agents, though clinical success remains limited. Recent studies also highlight FNTB's involvement in non-canonical substrates and metabolic pathways, expanding its potential therapeutic relevance. These antibodies thus support mechanistic investigations and biomarker discovery in precision medicine approaches.
×
